Case Report
Lymphoepithelioma-Like Carcinoma of the Breast: A Case Report Unveiling Several Clinical and Histopathological Challenges
Table 1
Table summarizing main clinicopathological parameters of LELC cases reported so far in world literature.
| | Number | Authors and reference | Year | Patient age (years) | Tumor size (cm) | Lymph node | ER | PR | Her2 | CK AE1/AE3 | EBV |
| | 1 | Kumar and Kumar [2] | 1994 | 65 | 2.0 | 0 | + | + | − | + | − | | 2 | Cristina et al. [17] | 2000 | 54 | 1.5 | 0/19 | + (42%) | − (<10%) | − | NA | − | | 3 | Dadmanesh et al. [14] | 2001 | 43 | 1.9 | 1/1 | − | − | − | NA | − | | 4 | 53 | 2.0 | | − | − | − | NA | − | | 5 | 49 | 1.0 | 0/19 | − | − | − | NA | − | | 6 | 52 | 2.7 | 0/20 | + | − | − | NA | − | | 7 | 64 | 2.0 | 0/29 | − | − | − | NA | − | | 8 | 69 | 2.3 | 0/19 | − | − | − | NA | − | | 9 | Naidoo and Chetty [18] | 2001 | 50 | 2.5 | 2/24 | NA | NA | NA | − | − | | 10 | Pestereli et al. [19] | 2002 | 56 | 2.0 | 2/27 | + | + | − | + | − | | 11 | Sanati et al. [11] | 2004 | 62 | 3.0 | NA | + (10%) | − | − | + | − | | 12 | Ilvan et al. [16] | 2004 | 59 | 3.5 | 0/20 | + | + | − | + | − | | 13 | 67 | 1.1 | 0/16 | − | − | − | + | − | | 14 | Kurose et al. [20] | 2005 | 47 | 2.8 | 0/33 | − | − | + | + | − | | 15 | Saleh et al. [12] | 2005 | 51 | 1.3 | 1/8 | − | − | NA | + | − | | 16 | Kulka et al. [7] | 2008 | 42 | 2.5 | 0/10 | + | − | − | + | − | | 17 | O’Sullivan-Mejia et al. [21] | 2009 | 55 | 3.1 | 0/2 | − | − | + | + | − | | 18 | Jeong et al. [22] | 2010 | 37 | 3.0 | 0/13 | − | − | + | + | − | | 19 | Dinniwell et al. [6] | 2012 | 55 | 4.0 | 0/2 | − | − | − | NA | − | | 20 | Nio et al. [3] | 2012 | 45 | 3.0 | 0/5 | − | − | − | NA | NA | | 21 | Suzuki et al. [23] | 2012 | 64 | 2.1 | 3/23 | − | − | + | NA | NA | | 22 | Trihia et al. [24] | 2012 | 53 | 1.5 | 2/30 | − | − | + | + | NA | | 23 | Abdou and Asaad [13] | 2014 | 45 | 2.0 | 0/24 | − | − | − | NA | − | | 24 | Top et al. [25] | 2014 | 59 | 3.0 | 0/23 | − | − | − | NA | − | | 25 | Nankin et al. [26] | 2015 | 39 | 2.7 | 0/5 | + (40%) | − | − | NA | NA | | 26 | Sato et al. [27] | 2016 | 50 | 1.2 | 1/23 | − | − | − | + | − | | 27 | Herrera-Goepfert et al. [28] | 2016 | 57 | 4.0 | 0 | + | + | − | + | − | | 28 | Shet et al. [1] | 2016 | 56 | 3.0 | 1/17 | − | − | − | NA | − | | 29 | 39 | 2.0 | 0/18 | − | − | − | NA | − | | 30 | 40 | 2.5 | NA | − | − | − | NA | − | | 31 | 40 | 3.5 | NA | − | − | − | NA | − | | 32 | 51 | 3.0 | NA | − | − | − | NA | − | | 33 | Present case | 2017 | 62 | 3.5 | 0/11 | − | − | − | + | NA |
|
|
ER: estrogen receptor; PR: progesterone receptor; Her2: Her2 receptor; CK: cytokeratin; EBV: Epstein-Barr virus; NA: not available.
|
